The key data on non-Hodgkin lymphoma presented at the 2022 American Society of Hematology Annual Meeting and Exposition are discussed by Dr Michael Bishop, from the University of Chicago, Illinois.
He begins with the MATRix/IELSG43 trial of consolidation therapy options in patients with primary central nervous system lymphoma. The study demonstrated that high-dose chemotherapy plus autologous stem cell transplantation is the new standard of care.
Dr Bishop then turns to a number of studies of bispecific antibodies, starting with an examination of relapse rates in patients with large B-cell lymphoma who achieve complete remission after treatment with glofitamab. The results were highly encouraging.
The ELM-2 study of odronextamab in diffuse large B-cell lymphoma is next, and this pivotal phase 2 trial demonstrated that odronextamab achieves clinically meaningful results.
Dr Bishop moves on to mosunetuzumab monotherapy in follicular lymphoma, which again showed durable efficacy and manageable safety in a phase 2 trial.
In closing, he reports on a comparison of rituximab and watch and wait in asymptomatic, low tumor burden follicular lymphoma. The study showed that, in this case, active treatment significantly delayed disease progression.
Medscape © 2023 WebMD, LLC
Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.
Cite this: Key Data in Non-Hodgkin Lymphoma From ASH 2022 - Medscape - Jan 03, 2023.
Comments